Related Experiment Video
Updated: Feb 10, 2026

Skin Tattooing As A Novel Approach For DNA Vaccine Delivery
Published on: October 18, 2012
A multifaceted approach to RSV vaccination
Jorge C G Blanco1, Marina S Boukhvalova1, Trudy G Morrison2
1a Sigmovir Biosystems Inc. , Rockville , MD.
Insights
Respiratory Syncytial Virus (RSV) vaccines are in clinical trials for infants, children, women, and the elderly. This review discusses current RSV vaccine candidates and preclinical studies to improve prediction of clinical outcomes.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory Syncytial Virus (RSV) is a major global cause of infant pneumonia and bronchiolitis.
- RSV circulates year-round, posing risks to infants, the elderly, and immunocompromised individuals.
- Currently, no approved vaccines exist to prevent RSV infection or mitigate its symptoms.
Purpose of the Study:
- To review and discuss RSV vaccine candidates in clinical trials.
- To describe preclinical studies supporting vaccine advancement.
- To propose novel preclinical models for predicting clinical vaccine trial success.
Main Methods:
- Literature review of current RSV vaccine clinical trials.
- Analysis of preclinical data supporting vaccine candidates.
- Discussion of existing and potential preclinical models for RSV vaccine evaluation.
Main Results:
- Multiple RSV vaccine candidates are in clinical development targeting diverse populations including infants, children, women, and adults/elderly.
- Preclinical studies have been crucial for advancing these vaccine candidates.
- There is a need for improved preclinical models to better predict clinical efficacy and safety.
Conclusions:
- RSV vaccine development is progressing across various age groups.
- Advancement relies on robust preclinical data.
- Enhanced preclinical models are essential for successful RSV vaccine translation to clinical practice.
Abstract:
Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, resulting in significant morbidity and mortality worldwide. In addition, RSV infections occur throughout different ages, thus, maintaining the virus in circulation, and increasing health risk to more susceptible populations such as infants, the elderly, and the immunocompromised. To date, there is no vaccine approved to prevent RSV infection or minimize symptoms of infection. Current clinical trials for vaccines against RSV are being carried out in four very different populations. There are vaccines that target two different pediatric populations, infants 2 to 6 month of age and seropositive children over 6 months of age, as well as women (non-pregnant or pregnant in their third trimester). There are vaccines that target adult and elderly populations. In this review, we will present and discuss RSV vaccine candidates currently in clinical trials. We will describe the preclinical studies instrumental for their advancement, with the goal of introducing new preclinical models that may more accurately predict the outcome of clinical vaccine studies.
More Related Videos
Related Concept Videos
Vaccinations
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Frustration and Conflict: Approach-Approach, Approach-Avoidance
One common type of conflict is the Approach–Approach Conflict. In this case, a person faces two desirable...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Information Processing Approach

